Kontakt
QR-Code für die aktuelle URL

Story Box-ID: 54158

Roche Diagnostics Deutschland GmbH Sandhofer Str. 116 68309 Mannheim, Deutschland http://www.roche.de/
Ansprechpartner:in Dr. Burkhard Ziebolz +49 8856 604830
Logo der Firma Roche Diagnostics Deutschland GmbH
Roche Diagnostics Deutschland GmbH

Genome Sequencer FLX System plus NimbleGen Sequence Capture Arrays

Help Unravel the Cryptic Genetic Changes in Hematological Malignancies

(lifePR) (Penzberg, )
The Cancer Genomics Group at Barts and The London Medical School is researching leukemia with the aquisition of the state-of-the-art Genome Sequencer FLX System paired with the Roche NimbleGen Sequence Capture arrays. Researchers, led by Professor Brian Young, will use the combined technology of 454 Sequencing and NimbleGen Sequence Capture Arrays to uncover the genetic changes that are involved in the development of leukemia. The new sequence information will be linked to an existing extensive clinical and cytogenetic database to investigate the relationship between genetic change and the clinical features of this devastating disease. The researchers expect that the new data could have implications for the future therapy and clinical outcome of hematological malignancies.

"454 Sequencing offers exciting new approaches to the investigation of cancer. Although many genes have been implicated in cancer, it is likely that there are many more that have yet to be discovered. The Cancer Genomics Group at Barts and The London Medical School is ideally placed to exploit this revolutionary technology. We wish to apply the massively parallel sequencing of 454 Sequencing to uncover all the genetic changes that initiate and drive the leukemia cells", says Young, head of the Cancer Genomics Group.

Planned research projects include the sequence analysis of key genes and genomic regions that are involved in acute myeloid leukemia (AML), analysis of microRNA expression profiles and paired-end analysis of microdeletion events. More precisely, using the Roche NimbleGen Sequence Capture Arrays, the researchers plan to capture a series of genes involved in the development of the disease, including those known to be mutated in AML such as FLT3 and MLL, and characterize putative mutation targets through SNP genotype analysis. Analyzing full sequences of mutated genes (including introns) with the help of the Genome Sequencer FLX System the researchers strive to uncover the genetic variations that drive the initiation and development of leukemia.

The Cancer Genomics Group also plans to use the technology of 454 Sequencing to investigate the full pattern of microRNA expression in AML and compare it to known gene expression profiles for other leukemia subtypes. Analysis of these microRNA expression profiles is likely to help further unraveling the etiology of leukemia and may evolve into a tool for cancer classification. The researchers will also examine microdeletions, a type of genetic abnormality that appears to be a common characteristic feature of leukemias. Up to now, detection of microdeletions was limited by the availability of SNP markers. The unique technology of 454 Sequencing allows for a genome-wide analysis of microdeletions; its unbiased approach will increase the likelihood of finding all such events.

Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.

NIMBLEGEN is a trademark of Roche.

Für die oben stehenden Stories, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Titel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Texte sowie der angehängten Bild-, Ton- und Informationsmaterialien. Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@lifepr.de.
Wichtiger Hinweis:

Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die unn | UNITED NEWS NETWORK GmbH gestattet.

unn | UNITED NEWS NETWORK GmbH 2002–2024, Alle Rechte vorbehalten

Für die oben stehenden Stories, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Titel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Texte sowie der angehängten Bild-, Ton- und Informationsmaterialien. Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@lifepr.de.